FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 337:339-341 July 31, 1997 Number 5 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited

The treatment of localized prostate cancer is a matter of considerable controversy. For decades experts vigorously debated the relative merits of radical prostatectomy and external-beam radiotherapy. During those years the proportion of patients who received radiotherapy remained high, because of the complications of surgery and the older age of the patients, and because most physicians believed that external-beam radiotherapy was the only cure for disease that had spread outside the prostate (i.e., stage T3 or T4).

In the past decade, however, the proportion of patients treated with radiation changed dramatically. Because of the widespread use of prostate-specific-antigen (PSA) testing for . . . [Full Text of this Article]

References

HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  TERMS OF USE  |  HELP  |  beta.nejm.org Comments and questions? Please contact us. The New England Journal of Medicine is owned, published, and copyrighted © 2009 Massachusetts Medical Society. All rights reserved.